Merck & Co., Inc. (MRK) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncolog...
Merck & Co., Inc.'s revenue increased 1.3% year over year, from $64.17B to $65.01B.
Net income increased 6.6% over the same period, from $17.12B to $18.25B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 63% in total.
Total debt increased by 32.9% to $49.34B.
The debt-to-equity ratio stands at 0.94, indicating a moderate leverage profile.
Operating cash flow declined 23.3% to $16.47B.
Merck & Co., Inc. maintains a strong net profit margin of 28.1%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $45.48B+54.1% | $1.59B | $33.27B | $3.94B | $12.76B | $106.73B | $34.86B | $41.25B |
| Q1 FY2024 | $15.78B-65.3% | $4.76B | $12.23B | $5.67B | $3.09B | $105.85B | $34.22B | $40.36B |
| Q2 FY2024 | $31.89B+102.1% | $10.22B | $24.60B | $11.68B | $8.73B | $112.63B | $37.79B | $43.58B |
| Q3 FY2024 | $48.54B+52.2% | $13.37B | $37.18B | $15.77B | $18.02B | $117.53B | $38.13B | $44.50B |
| Q1 FY2025 | $15.53B-68.0% | $5.08B | $12.11B | $5.90B | $2.50B | $115.12B | $34.84B | $48.34B |
| Q2 FY2025 | $31.34B+101.8% | $9.51B | $24.36B | $10.90B | $5.79B | $117.52B | $35.40B | $48.99B |
| Q3 FY2025 | $48.61B+55.1% | $15.29B | $37.78B | $17.65B | $13.62B | $129.55B | $41.37B | $51.85B |
| Q1 FY2026 | $16.29B-66.5% | $-4.24B | $12.09B | $-3.53B | $3.92B | $128.69B | $49.12B | $45.88B |
Balance Sheet Summary (Latest Period)
Total Assets
$136.87B
Total Liabilities
$84.26B
Total Equity
$52.61B
Cash & Equivalents
$14.56B
Total Debt
$49.34B
Current Assets
$43.52B
Current Liabilities
$28.33B
Retained Earnings
$73.08B